Sol-gel technologies provides update on fda review of epsolay®

Ness ziona, israel, april 27, 2021 (globe newswire) -- sol-gel technologies, ltd. (nasdaq: slgl), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced an update regarding the u.s. food and drug administration (fda) approval process for epsolay® (benzoyl peroxide) 5% topical cream for the treatment of inflammatory lesions of rosacea in adults.
SLGL Ratings Summary
SLGL Quant Ranking